Business Context and Reporting Period
This Form 6-K filing by Regentis Biomaterials Ltd. covers the month of January 2026, with the report dated January 6, 2026. The filing primarily addresses a significant change in executive leadership effective December 31, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding corporate governance rather than a financial results statement.
Material Changes
- CEO Resignation: Dr. Eli Hazum resigned as Chief Executive Officer effective December 31, 2025. The resignation is attributed to personal reasons and is not due to any disagreement with the Company.
- CEO Appointment: Dr. Ehud Geller, the Chairman of the Board of Directors, was appointed as the new Chief Executive Officer on the same day.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the leadership transition. No unusual items were reported.
Investor Verification Checklist
- Confirm the effective date of Dr. Hazum's departure and Dr. Geller's appointment.
- Review the Company's Form 20-F for the most recent audited financial statements, as this 6-K contains no financial data.
- Monitor future filings for any strategic shifts resulting from the new CEO's leadership.